News – Page 1063 – Endpoints News

Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos

8 years ago

Google backs $27M launch round for Holy Grail R&D work on two targets: a cancer vaccine and a universal flu jab

8 years ago

Scoop: With its NDA in limbo, Ironshore execs shuttered the ADHD biotech

8 years ago

Video: How many PD-1/L1 drugs do we need? Where is immunotherapy headed? Watch Jay Bradner, Hervé Hoppenot, Ellen ...

8 years ago

HHS pick Azar draws the line on drug price negotiations at Medicare; AstraZeneca inks oncology research deal at JPM

8 years ago

In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer

8 years ago

The Cambridge siren call: Philips NV moving HQ to mega-project Cambridge Crossing

8 years ago

Why did Ablynx board chairman Peter Fellner resign in wake of Novo's buyout offer?; Amgen vet Richard Paulson tapped ...

8 years ago

Jumping on anti-aging bandwagon, Y Combinator joins hunt for the $100B pill

8 years ago

Headed for a blockbuster smash, Roche picks up another key OK for landmark MS drug Ocrevus

8 years ago

Genentech beefs up its PD-L1 combo pipeline, signing the 'don’t eat me' specialists at Forty Seven

8 years ago

Braeburn bags $110M in launch cash as PDUFA date rolls up; Endo subpoenaed for documents on opioid painkillers

8 years ago

New study looks at FDA's use of social media to communicate on drug safety

8 years ago

Teva's board slashes its own compensation following massive restructuring

8 years ago

Shire CEO Flemming Ornskov is hatching a few new stretch goals for R&D in 2018 — and beyond

8 years ago

Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint

8 years ago

Pfizer oncology head Liz Barrett jumps ship to Novartis as Bruno Strigini steps aside

8 years ago

The FDA still hates low T drugs — experts bat back a pair of contenders

8 years ago

Moderna expands pipeline to include liver disease programs; Imperial researchers team up with Heptares on ...

8 years ago

Truffle roots for new biotechs after first close of a planned $240M fund

8 years ago

Genentech adds a new program for Syndax’s lead cancer drug to its Tecentriq combo platform

8 years ago

Bluebird hopes for 3 drug approvals by 2019, including CAR-T and gene therapies

8 years ago

GSK’s long-quiet cancer R&D group is ready to make some noise as it mounts a breakout late-stage effort

8 years ago

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

8 years ago

First page Previous page 1060 1061 106210631064 1065 1066 Next page Last page